Alexandre Escande

Alexandre Escande

Auto-generated profile, based on publicly available information

Alexandre Escande

Département de radiothérapie, centre Léonard-de-Vinci, Dechy, France; Laboratoire CRIStAL, UMR 9186, université de Lille, Villeneuve-d'Ascq, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Jean-Emmanuel BibaultJean-Emmanuel Bibault
Jean-Emmanuel Bibault
BCBenjamin Chaix
Benjamin Chaix
AGArthur Guillemassé
Arthur Guillemassé
SCSophie Cousin
Sophie Cousin
AEAlexandre Escande
Alexandre Escande
BBBenoît Brouard
Benoît Brouard
Background: The data regarding the use of conversational agents in oncology are scarce. Objective: The aim of this study was to verify whether an artificial conversational agent was able to provide answers to patients with breast cancer with a level of satisfaction similar to the answers given by a group of physicians. Methods: This study is a blind, noninferiority randomized controlled trial that compared the information given by the chatbot, Vik, with that given by a multidisciplinary group of physicians to patients with breast cancer. Patients were women with breast cancer in treatment or in remission. The European Organisation for Research and Treatment of Cancer Quality of Life Group information questionnaire (EORTC QLQ-INFO25) was adapted and used to compare the quality of the information provided to patients by the physician or the chatbot. The primary outcome was to show that the answers given by the Vik chatbot to common questions asked by patients with breast cancer about their therapy management are at least as satisfying as answers given by a multidisciplinary medical committee by comparing the success rate in each group (defined by a score above 3). The secondary objective was to compare the average scores obtained by the chatbot and physicians for each INFO25 item. Results: A total of 142 patients were included and randomized into two groups of 71. They were all female with a mean age of 42 years (SD 19). The success rates (as defined by a score >3) was 69% (49/71) in the chatbot group versus 64% (46/71) in the physicians group. The binomial test showed the noninferiority (P<.001) of the chatbot’s answers. Conclusions: This is the first study that assessed an artificial conversational agent used to inform patients with cancer. The EORTC INFO25 scores from the chatbot were found to be noninferior to the scores of the physicians. Artificial conversational agents may save patients with minor health concerns from a visit to the doctor. This could allow clinicians to spend more time to treat patients who need a consultation the most. Trial Registration: Clinicaltrials.gov NCT03556813, https://tinyurl.com/rgtlehq

1 December 2020 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
CCChristian Carrie
Christian Carrie
VKVirginie Kieffer
Virginie Kieffer
DFDominique Figarella-Branger
Dominique Figarella-Branger
JMJulien Masliah-Planchon
Julien Masliah-Planchon
SBStéphanie Bolle
Stéphanie Bolle
LPLaetitia Padovani
Laetitia Padovani

1 September 2017 in Brachytherapy
Verified
Journal Article
Closed access
ASAntoine Schernberg
Antoine Schernberg
CBCorinne Balleyguier
Corinne Balleyguier
IDIsabelle Dumas
Isabelle Dumas
SGSébastien Gouy
Sébastien Gouy
AEAlexandre Escande
Alexandre Escande
CCCyrus Chargari
Cyrus Chargari

7 August 2019 in JMIR Preprints
Verified
Preprint
Open access
Jean-Emmanuel BibaultJean-Emmanuel Bibault
Jean-Emmanuel Bibault
BCBenjamin Chaix
Benjamin Chaix
AGArthur Guillemassé
Arthur Guillemassé
SCSophie Cousin
Sophie Cousin
AEAlexandre Escande
Alexandre Escande
BBBenoît Brouard
Benoît Brouard
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The data regarding the use of conversational agents in oncology are scarce. Objective: The aim of this study was to verify whether an artificial conversational agent was able to provide answers to patients with breast cancer with a level of satisfaction similar to the answers given by a group of physicians. Methods: This study is a blind, noninferiority randomized controlled trial that compared the information given by the chatbot, Vik, with that given by a multidisciplinary group of physicians to patients with breast cancer. Patients were women with breast cancer in treatment or in remission. The European Organisation for Research and Treatment of Cancer Quality of Life Group information questionnaire (EORTC QLQ-INFO25) was adapted and used to compare the quality of the information provided to patients by the physician or the chatbot. The primary outcome was to show that the answers given by the Vik chatbot to common questions asked by patients with breast cancer about their therapy management are at least as satisfying as answers given by a multidisciplinary medical committee by comparing the success rate in each group (defined by a score above 3). The secondary objective was to compare the average scores obtained by the chatbot and physicians for each INFO25 item. Results: A total of 142 patients were included and randomized into two groups of 71. They were all female with a mean age of 42 years (SD 19). The success rates (as defined by a score >3) was 69% (49/71) in the chatbot group versus 64% (46/71) in the physicians group. The binomial test showed the noninferiority (P<.001) of the chatbot’s answers. Conclusions: This is the first study that assessed an artificial conversational agent used to inform patients with cancer. The EORTC INFO25 scores from the chatbot were found to be noninferior to the scores of the physicians. Artificial conversational agents may save patients with minor health concerns from a visit to the doctor. This could allow clinicians to spend more time to treat patients who need a consultation the most. Clinical Trial: Clinicaltrials.gov NCT03556813, https://tinyurl.com/rgtlehq

1 June 2021 in Revue D'Épidémiologie Et de Santé Publique
Verified
Journal Article
Closed access
ALA. Lecoeuvre
A. Lecoeuvre
CLC. Léguillette
C. Léguillette
AEA. Escande
A. Escande
FRF. Rotolo
F. Rotolo
ETE. Tresch
E. Tresch
MDM. Le Deley
M. Le Deley

1 November 2021 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
XLXiaokun Liang
Xiaokun Liang
Jean-Emmanuel BibaultJean-Emmanuel Bibault
Jean-Emmanuel Bibault
TLT. Leroy
T. Leroy
AEA. Escande
A. Escande
WZW. Zhao
W. Zhao
Lei XingLei Xing
Lei Xing